Shareholder''s Meeting is going to be held on 31st Day of July,2025
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Concord Drugs has called an EGM on 31st July 2025 (via video conferencing) to seek shareholder approval for three key items. First, increase authorized share capital from Rs. 11 crore to Rs. 15.5 crore (1.1 crore to 1.55 crore shares of Rs. 10 each) to create headroom for the upcoming issues. Second, issue 31.75 lakh equity shares on a preferential basis at Rs. 36.30 per share (including a Rs. 26.30 premium), raising up to Rs. 11.52 crore from promoters (S Nagi Reddy, S Koni Reddy, S Manoj Kumar Reddy) and several non-promoter allottees. Third, issue 20.25 lakh convertible warrants at Rs. 36.30 each to promoters and one identified non-promoter, potentially raising an additional Rs. 7.35 crore if converted within 18 months. The relevant date for pricing is 1st July 2025, with lock-in rules under SEBI ICDR Regulations applying.
This is a meaningful capital raise that could dilute existing shareholders by roughly 29% via the equity issue, with a further ~18% potential dilution if all warrants are converted (total potential dilution around 47%). Promoters are participating alongside outside investors, which is mildly reassuring, but retail shareholders should weigh the dilution impact carefully. The funds raised are intended to strengthen the company's capital base, though end-use details will be in the explanatory statement.